Literature DB >> 33077484

Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.

Yongjie Ma1, Xiaohan Zhang1, Omar Awad Alsaidan1, Xiangkun Yang1, Essilvo Sulejmani1, Junyi Zha1, Zanna Beharry2, Hanwen Huang3, Michael Bartlett1, Zachary Lewis4, Houjian Cai5.   

Abstract

Androgen deprivation therapy has led to elevated cases of androgen receptor (AR) pathway-independent prostate cancer with dysregulated fatty acid metabolism. However, it is unclear how prostate cancer cells sustain dysregulated fatty acid metabolism to drive AR-independent prostate cancer. Long-chain acyl-CoA synthetases (ACSL) catalyze the conversion of fatty acids into fatty acyl-CoAs that are required for fatty acid metabolism. In this study, we demonstrate that expression levels of ACSL3 and 4 were oppositely regulated by androgen-AR signaling in prostate cancer cells. AR served as a transcription suppressor to bind at the ACSL4 promoter region and inhibited its transcription. Inhibition of androgen-AR signaling significantly downregulated ACSL3 and PSA, but elevated ACSL4 levels. ACSL4 regulated a broad spectrum of fatty acyl-CoA levels, and its catalytic efficiency in fatty acyl-CoAs biosynthesis was about 1.9- to 4.3-fold higher than ACSL3. In addition, in contrast to ACSL3, ACSL4 significantly regulated global protein myristoylation or myristoylation of Src kinase in prostate cancer cells. Knockdown of ACSL4 inhibited the proliferation, migration, invasion, and xenograft growth of AR-independent prostate cancer cells. Our results suggest that the surge of ACSL4 levels by targeting AR signaling increases fatty acyl-CoAs biosynthesis and protein myristoylation, indicating the opposite, yet complementary or Yin-Yang regulation of ACSL3 and 4 levels in sustaining fatty acid metabolism when targeting androgen-AR signaling. This study reveals a mechanistic understanding of ACSL4 as a potential therapeutic target for treatment of AR-independent prostate cancer. IMPLICATIONS: AR coordinately regulates the expression of ACSL3 and ACSL4, such that AR pathway-independent prostate tumors become dependent on ACSL4-mediated fatty acid metabolism. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33077484      PMCID: PMC7785683          DOI: 10.1158/1541-7786.MCR-20-0379

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  50 in total

1.  Survey of the fatty acid composition of retail milk in the United States including regional and seasonal variations.

Authors:  A M O'Donnell-Megaro; D M Barbano; D E Bauman
Journal:  J Dairy Sci       Date:  2011-01       Impact factor: 4.034

2.  Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Authors:  Clarissa Gerhauser; Francesco Favero; Thomas Risch; Ronald Simon; Lars Feuerbach; Yassen Assenov; Doreen Heckmann; Nikos Sidiropoulos; Sebastian M Waszak; Daniel Hübschmann; Alfonso Urbanucci; Etsehiwot G Girma; Vladimir Kuryshev; Leszek J Klimczak; Natalie Saini; Adrian M Stütz; Dieter Weichenhan; Lisa-Marie Böttcher; Reka Toth; Josephine D Hendriksen; Christina Koop; Pavlo Lutsik; Sören Matzk; Hans-Jörg Warnatz; Vyacheslav Amstislavskiy; Clarissa Feuerstein; Benjamin Raeder; Olga Bogatyrova; Eva-Maria Schmitz; Claudia Hube-Magg; Martina Kluth; Hartwig Huland; Markus Graefen; Chris Lawerenz; Gervaise H Henry; Takafumi N Yamaguchi; Alicia Malewska; Jan Meiners; Daniela Schilling; Eva Reisinger; Roland Eils; Matthias Schlesner; Douglas W Strand; Robert G Bristow; Paul C Boutros; Christof von Kalle; Dmitry Gordenin; Holger Sültmann; Benedikt Brors; Guido Sauter; Christoph Plass; Marie-Laure Yaspo; Jan O Korbel; Thorsten Schlomm; Joachim Weischenfeldt
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

3.  Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression.

Authors:  Sungjin Kim; Omar Awad Alsaidan; Octavia Goodwin; Qianjin Li; Essilvo Sulejmani; Zhen Han; Aiping Bai; Thomas Albers; Zanna Beharry; Y George Zheng; James S Norris; Zdzislaw M Szulc; Alicja Bielawska; Iryna Lebedyeva; Scott D Pegan; Houjian Cai
Journal:  Cancer Res       Date:  2017-10-16       Impact factor: 12.701

4.  A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis.

Authors:  M J Kang; T Fujino; H Sasano; H Minekura; N Yabuki; H Nagura; H Iijima; T T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.

Authors:  Hongjuan Zhao; Young Kim; Pei Wang; Jacques Lapointe; Rob Tibshirani; Jonathan R Pollack; James D Brooks
Journal:  Prostate       Date:  2005-05-01       Impact factor: 4.104

6.  Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.

Authors:  Qianjin Li; Omar Awad Alsaidan; Yongjie Ma; Sungjin Kim; Junchen Liu; Thomas Albers; Kebin Liu; Zanna Beharry; Shaying Zhao; Fen Wang; Iryna Lebedyeva; Houjian Cai
Journal:  J Biol Chem       Date:  2018-03-14       Impact factor: 5.157

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

8.  CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.

Authors:  L Wu; C Runkle; H-J Jin; J Yu; J Li; X Yang; T Kuzel; C Lee; J Yu
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

9.  Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1.

Authors:  Kevin J French; Yan Zhuang; Randy S Schrecengost; Jean E Copper; Zuping Xia; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2004-01-14       Impact factor: 4.030

10.  Targeting protein myristoylation for the treatment of prostate cancer.

Authors:  Essilvo Sulejmani; Houjian Cai
Journal:  Oncoscience       Date:  2018-01-22
View more
  4 in total

1.  The Yin-Yang Dynamics in Cancer Pharmacogenomics and Personalized Medicine.

Authors:  Qing Yan
Journal:  Methods Mol Biol       Date:  2022

2.  MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin.

Authors:  Yakun Luo; Virginie Vlaeminck-Guillem; Silvère Baron; Sarah Dallel; Chang Xian Zhang; Muriel Le Romancer
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

3.  Genetic Alteration, Prognostic and Immunological Role of Acyl-CoA Synthetase Long-Chain Family Member 4 in a Pan-Cancer Analysis.

Authors:  Yongsheng Yu; Xuepu Sun; Fei Chen; Miao Liu
Journal:  Front Genet       Date:  2022-01-20       Impact factor: 4.599

Review 4.  ACSL4 as a Potential Target and Biomarker for Anticancer: From Molecular Mechanisms to Clinical Therapeutics.

Authors:  Jun Hou; Changqing Jiang; Xudong Wen; Chengming Li; Shiqiang Xiong; Tian Yue; Pan Long; Jianyou Shi; Zhen Zhang
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.